Zusammenfassung
Immunneuropathien stellen eine äußerst heterogene Gruppe von zum Teil akut, zum überwiegenden Teil chronisch verlaufenden Erkrankungen mit gravierender Morbidität dar, die das periphere Nervensystem in verschiedenen Facetten betreffen. In den zurückliegenden Jahren konnten große Fortschritte im Verständnis pathogenetisch relevanter Mechanismen erzielt werden. So ist die Rolle von T-Lymphozyten oder die Relevanz von anti-Gangliosid-Antikörpern bei der Schädigung zellulärer Strukturen im peripheren Nerv besser verstanden. Neuere klinische Studien unterstreichen die Bedeutung immunmodulierender und -supprimierender Therapiestrategien, wobei weiterhin Bedarf zur Entwicklung wirksamerer Therapieoptionen besteht, um diese mit Langzeitbehinderung assoziierten Erkrankungen besser behandeln zu können.
Abstract
Immune-mediated neuropathies represent a heterogeneous group of in part acute and, in the majority, chronic diseases affecting the peripheral nerves and still being associated with serious morbidity. In recent years advances in the understanding of pathogenetically relevant mechanisms could be obtained. An emerging body of evidence underlines the role of T lymphocytes or the relevance of anti-ganglioside antibodies in mediating damage to cellular structures within the peripheral nerves. Recent clinical trials point to the impact of immunomodulating and -suppressive drugs in CIDP, however, there is an urgent need for even more powerful treatment strategies in order to prevent long-term disability in patients diagnosed with immune-mediated neuropathies.
Schlüsselwörter
Immunneuropathien - Guillain-Barré-Syndrom - CIDP - Therapie
Key words
immune neuropathies - Guillain-Barré syndrome - CIDP - therapy
Literatur
-
1
Hughes R AC, Cornblath D R.
Guillain-Barré syndrome.
Lancet.
2005;
366
1653-1666
-
2
Köller H, Kieseier B C, Jander S. et al .
Chronic inflammatory demyelinating polyneuropathy.
N Engl J Med.
2005;
352
1343-1356
-
3
Hughes R AC.
The concept and classification of Guillain-Barré syndrome and related disorders.
Rev Neurol (Paris).
1995;
151
291-294
-
4
Feasby T E.
Axonal Guillain-Barré syndrome.
Muscle Nerve.
1994;
17
678-679
, (Brain 1996; 119: 1055 - 1066)
-
5
Willison H J, O'Hanlon G M.
The immunopathogenesis of Miller Fisher syndrome.
J Neuroimmunol.
1999;
100
3-12
-
6
Hughes R AC, Wijdicks E F, Barohn R. et al .
Practice parameter: Immunotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Neurology.
2003;
61
736-740
-
7
Kusunoki S, Chiba A, Kanazawa I.
Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia.
Muscle Nerve.
1999;
22
1071-1074
-
8
Koga M, Yuki N, Ariga T. et al .
Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome?.
J Neuroimmunol.
1998;
86
74-79
-
9
Ropper A H.
Unusual clinical variants and signs in Guillain-Barré syndrome.
Arch Neurol.
1986;
43
1150-1152
-
10
O'Leary C P, Veitch J, Durward W F. et al .
Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides.
J Neurol Neurosurg Psychiatry.
1996;
61
649-651
-
11
Katz J S, Saperstein D S, Gronseth G. et al .
Distal acquired demyelinating symmetric neuropathy.
Neurology.
2000;
54
615-620
-
12
Saperstein D S, Katz J S, Amato A A, Barohn R J.
Clinical spectrum of chronic acquired demyelinating polyneuropathies.
Muscle Nerve.
2001;
24
311-324
-
13
Van den Berg-Vos R M, van den Berg L H, Franssen H. et al .
Multifokal inflammatory demyelinating polyneuropathy. A distinct clinical entitiy?.
Neurology.
2000;
54
26-32
-
14
Hughes R AC, Umapathi T, Gray I A. et al .
A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy.
Brain.
2004;
127
1723-1730
-
15
Sabatelli M, Madia F, Mignogna T. et al .
Pure motor chronic inflammatory demyelinating polyneuropathy.
J Neurol.
2001;
248
772-777
-
16
Dyck P J, Dyck P JB.
Atypical varieties of chronic inflammatory demyelinating neuropathies.
Lancet.
2000;
355
1293-1294
-
17
Hughes R AC, Bensa S, Willison H. et al .
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.
Ann Neurol.
2001;
50
195-201
-
18
The French CIDP Study Group .
Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy.
J Neurol Neurosurg Psychiatry.
2008;
79
115-118
-
19
Meyer zu Hörste G, Hartung H P, Kieseier B C.
From bench to bedside - experimental rationale for immune-specific therapies in the inflamed peripheral nerve.
Nat Clin Pract Neurol.
2007;
3
198-211
-
20
Hu W, Dehmel T, Pirhonen J. et al .
Interleukin-23 in acute inflammatory demyelination of the peripheral nervous system.
Arch Neurol.
2006;
63
858-864
-
21
Hu W, Janke A, Ortler S. et al .
Expression of CD28 related costimulatory molecule and its ligand in inflammatory neuropathies.
Neurology.
2007;
68
277-282
-
22
Willison H J, Yuki N.
Peripheral neuropathies and anti-glycolipid antibodies.
Brain.
2002;
125
2591-2625
-
23
Yuki N.
Carbohydrate mimicry: a new paradigm of autoimmune diseases.
Curr Opin Immunol.
2005;
17
577-582
-
24
Griffin J W, Li C Y, Ho T W. et al .
Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases.
Brain.
1995;
118
577-595
-
25
Lehmann H C, Koehne A, Meyer zu Hörste G. et al .
Role of nitric oxide as mediators of nerve injury in inflammatory neuropathies.
J Neuropathol Exp Neurol.
2007;
66
305-312
-
26
Khalili-Shirazi A, Atkinson P, Gregson N, Hughes R A.
Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy.
J Neuroimmunol.
1993;
46
245-251
-
27
Quattrini A, Previtali S C, Kieseier B C. et al .
Autoimmunity in the peripheral nervous system.
Critical Reviews in Neurobiology.
2003;
15
1-39
-
28
Steck A J, Stalder A K, Renaud S.
Anti-myelin-associated glycoprotein neuropathy.
Curr Opin Neurol.
2006;
19
458-463
-
29
Lehmann H C, Hartung H P, Hetzel G R. et al .
Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders.
Arch Neurol.
2006;
63
1066-1071
-
30
The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome .
Appropriate number of plasma exchanges in Guillain-Barré syndrome.
Ann Neurol.
1997;
41
298-306
-
31
Gold R, Stangel M, Dalakas M C.
Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues.
Nat Clin Pract Neurol.
2007;
3
36-44
-
32
Pritchard J, Gray I A, Idrissova Z R. et al .
A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.
Neurology.
2003;
61
1282-1284
-
33
Jacobs B C, van Doorn P A, Schmitz P I. et al .
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome.
Ann Neurol.
1996;
40
181-187
-
34
Rotta F T, Sussman A T, Bradley W G. et al .
The spectrum of chronic inflammatory demyelinating polyneuropathy.
J Neurol Sci.
2000;
173
129-139
-
35
Yuki N, Ang C W, Koga M. et al .
Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.
Ann Neurol.
2000;
47
314-321
-
36
Kieseier B C, Kiefer R, Gold R. et al .
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.
Muscle Nerve.
2004;
30
131-156
-
37
Hughes R AC, Swan A V, Raphael J C. et al .
Immunotherapy for Guillain-Barré syndrome: a systematic review.
Brain.
2007;
130
2245-2257
-
38
Guillain-Barré Syndrome Steroid Trial Group .
Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome.
Lancet.
1993;
341
586-590
-
39
van Koningsveld R, Schmitz P I, Meché F G. et al .
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
Lancet.
2004;
363
192-196
-
40
Köller H, Schroeter M, Kieseier B C, HP H artung.
Chronic inflammatory demyelinating neuropathy - update on pathogenesis, diagnostic criteria and therapy.
Curr Opin Neurol.
2005;
18
273-278
-
41
Kieseier B C, Wiendl H, Hartung H P.
The inflamed peripheral nervous system: update on immune therapies.
Curr Opin Neurol.
2006;
19
433-436
-
42
Gold R, Kieseier B C.
Therapy of immune neuropathies with intravenous immunoglobulins.
Journal of Neurology.
2006;
253
59-63
-
43
Hughes R AC, Donofrio P, Bril V. et al .
Intravenous immune globulin (10 % caprylatechromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Lancet Neurol.
2008;
7
136-144
-
44
Köller H, Schroeter M, Feischen H. et al .
Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.
J Neurol.
2006;
253
1505-1506
-
45 Lee D H, Linker R A, Paulus W. et al .Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008; in press
-
46
Kieseier B C, Dalakas M C, Hartung H P.
Immune mechanisms in chronic inflammatory demyelinating neuropathy.
Neurology.
2002;
59
7-12
-
47
Nobile-Orazio E, Cappellari A, Priori A.
Multifocal motor neuropathy: current concepts and controversies.
Muscle Nerve.
2005;
31
663-680
-
48
Federico P, Zochodne D W, Hahn A F. et al .
Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled study.
Neurology.
2000;
55
1256-1262
-
49
Koski C L.
Initial and long-term management of autoimmune neuropathies.
CNS Drugs.
2005;
19
1033-1048
-
50
Umapathi T, Hughes R A, Nobile-Orazio E, Leger J M.
Immunosuppressive treatment for multifocal motor neuropathy.
Cochrane Database Syst Rev.
2002;
, CD003217
-
51 Lehmann H C, Hoffmann F, Meyer zu Hörste G. et al .The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 2008; in press
-
52
Dyck P J, Daube J, O'Brien P. et al .
Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.
N Engl J Med.
1986;
314
461-465
-
53
Hahn A F, Bolton C F, Pillay N. et al .
Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.
Brain.
1996;
119
1055-1066
-
54
Lehmann H C, Hartung H P, Hetzel G R, Kieseier B C.
Plasmapherese als Therapieoption bei neurologischen Erkrankungen.
Der Nervenarzt.
2007;
78
166, 168 - 170, 172 - 176
-
55
Mehndiratta M M, Hughes R A.
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane Database Syst Rev.
2002;
, CD002062
-
56
Lopate G, Pestronk A, Al-Lozi M.
Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
Arch Neurol.
2005;
62
249-254
-
57
Dyck P J, O'Brien P, Swanson C. et al .
Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy.
Neurology.
1985;
35
1173-1176
-
58
Fialho D, Chan Y C, Allen D C. et al .
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate.
J Neurol Neurosurg Psychiatry.
2006;
77
544-547
-
59
Mahattanakul W, Crawford T O, Griffin J W. et al .
Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.
J Neurol Neurosurg Psychiatry.
1996;
60
185-187
-
60
Visudtibhan A, Chiemchanya S, Visudhiphan P.
Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy.
Pediatr Neurol.
2005;
33
368-372
-
61
Frohman E M, Brannon K, Racke M K, Hawker K.
Mycophenolate mofetil in multiple sclerosis.
Clin Neuropharmacol.
2004;
27
80-83
-
62
Schneider-Gold C, Hartung H P, Gold R.
Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases.
Muscle Nerve.
2006;
34
284-291
-
63
Gorson K C, Amato A A, Ropper A H.
Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.
Neurology.
2004;
63
715-717
-
64
Piepers S, van den Berg-Vos R, van der Pol W L.
Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.
Brain.
2007;
130
2004-2010
-
65
Gladstone D E, Prestrud A A, Brannagan T H.
High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy.
J Peripher Nerv Syst.
2005;
10
11-16
-
66
Glennie M J, French R R, Cragg M S, Taylor R P.
Mechanisms of killing by anti-CD20 monoclonal antibodies.
Mol Immunol.
2007;
44
3823-3837
-
67
Renaud S, Gregor M, Fuhr P. et al .
Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.
Muscle Nerve.
2003;
27
611-615
-
68
Renaud S, Fuhr P, Gregor M. et al .
High-dose rituximab and anti-MAG-associated polyneuropathy.
Neurology.
2006;
66
742-744
-
69
Ruegg S J, Fuhr P, Steck A J.
Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.
Neurology.
2004;
63
2178-2179
-
70
Broglio L, Lauria G.
Worsening after rituximab treatment in anti-mag neuropathy.
Muscle Nerve.
2005;
32
378-379
-
71
Browning J L.
B cells move to centre stage: novel opportunities for autoimmune disease treatment.
Nat Rev Drug Discov.
2006;
5
564-576
-
72
Hirst C, Raasch S, Llewelyn G, Robertson N.
Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).
J Neurol Neurosurg Psychiatry.
2006;
77
800-802
-
73
Report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force .
Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).
Neurology.
1991;
41
617-618
Prof. Dr. Bernd C. Kieseier
Neurologische Klinik, Heinrich-Heine-Universität
Moorenstr. 5
40225 Düsseldorf
Email: bernd.kieseier@uni-duesseldorf.de
